E. Laille

发表

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

Suzanne F. Jones, H. Burris, J. Infante, 2015, Journal of clinical pharmacology.

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

K. Kolibaba, B. Skikne, John C. Morris, 2018, American journal of hematology.

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

C. Craddock, B. Skikne, R. Champlin, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

P. Vyas, B. Skikne, G. Garcia-Manero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

Azacitidine is removed effectively by hemodialysis

G. Mayer, R. Stauder, H. Neuwirt, 2020, Leukemia & lymphoma.

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

A. Mita, N. Gabrail, S. Goel, 2014, Pharmacotherapy.

Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher‐risk myelodysplastic syndromes

Tsai-Yun Chen, W. Chou, S. Yeh, 2017, Asia-Pacific journal of clinical oncology.

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

A. Yang, H. Kantarjian, G. Garcia-Manero, 2007 .

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

B. Skikne, G. Garcia-Manero, S. Gore, 2009 .

Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies

B. Skikne, M. Savona, B. Scott, 2014, Journal of clinical pharmacology.

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine

S. Surapaneni, E. Laille, Gondi N. Kumar, 2010, Cancer Chemotherapy and Pharmacology.

Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

R. Martell, M. Crump, D. Rizzieri, 2008 .

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, E. Chan, B. Nelson, 2007 .

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

B. Skikne, M. Abdelrahim, M. Milhem, 2020, Cancer Chemotherapy and Pharmacology.

Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles (Caretta caretta).

E. Jacobson, L. Maxwell, Glenn R. Harman, 2003, American journal of veterinary research.

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2010 .

Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment

Liangang Liu, Richard A. Preston, Mahmoud S. Assaf, 2014, Int. J. Medical Eng. Informatics.

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

G. Rosner, K. Kelly, M. Carducci, 2020, Clinical Cancer Research.

Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

M. Taniwaki, M. Ogura, T. Ikezoe, 2017, International Journal of Hematology.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

B. Skikne, G. Garcia-Manero, S. Gore, 2015, PloS one.

Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study

Zhi-xiang Shen, Jie Jin, A. Sun, 2018, Asia-Pacific journal of clinical oncology.

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

J. Schellens, E. Heath, P. LoRusso, 2018, Clinical Cancer Research.

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

H. Döhner, P. Vyas, F. Thol, 2022, Blood.

A phase Ia study of CC-90003, a selective extracellular signal regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.

Edward S. Kim, P. LoRusso, J. Bendell, 2017 .

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

B. Skikne, G. Garcia-Manero, S. Gore, 2012 .

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

B. Skikne, G. Garcia-Manero, S. Gore, 2011 .

Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2014, Journal of pharmaceutical and biomedical analysis.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.